BioRelianc?e Expands Commercial Capabiliti?es of Big Blue Assay
BioReliance, Sigma-Aldrich Corporation’s biologics and early-development services business under SAFC Commercial (www.sigmaaldrich.com/safc), has expanded commercial availability of its exclusive Big Blue Transgenic Rodent Mutation (TRM) assay to identify and measure mutations in somatic tissue and germ cells. The assay enables follow-up testing of pharmaceutical and chemical products that have shown positive results in genotoxicity or carcinogenicity assays and can be used to investigate possible mutagenic modes of action. This test is now available for use with either mouse or rat subjects.
Big Blue TRM is the only assay of its kind on the market that
• Has been validated for application to measure mutations in both mice and rats, allowing the investigation of earlier results in both species
• Was developed through support from the National Institute of Environmental Health Sciences’ National Toxicology Program (NTP)
• Features mouse and rat strains designed to be identical to mouse and rat strains used in NTP carcinogenicity studies
• Is under the ownership and guidance of an original developer of the assay
• Features complete control of animal colonies to ensure animal availability
• Works with inbred homozygous mouse and rat lines to permit cross-breeding with other transgenic lines to investigate mutagenicity associated with disease conditions
• Offers comprehensive assay support and access to the expertise of BioReliance scientists.
Other differentiating factors of the Big Blue assay include
• Qualification to meet Organisation for Economic Co-operation and Development Test Guideline 488 requirements for evaluation of in vivo somatic cell and germ cell mutagenicity
• Endorsement by the International Working Group for Genetic Toxicology (IWGT)
• Recommendation by the European Chemicals Agency and referenced in ICH, FDA, EMEA, and EFSA Guidelines
• Robust mutant frequency detection (p<.00001)
• 3R alignment – previous in vivo mutation options used hundreds of animals compared to study sizes of 25
• The ability to investigate mutagenic mode of action after genotoxic positives in almost any tissue of the body.
BioReliance is making multiple presentations on the assay at this week’s Society of Toxicology’s 53rd Annual Meeting and Tox Expo, through the 27th in Phoenix, as follows:
• Tuesday, 25 March at 11:00 a.m. in Room 106C West: “Big Blue Transgenic Rodent Mutation Assay and Novel Renal Proximal Tubule Epithelial Cell Line (RPTECs) – Fulfillment of an Unmet Need in Genetic Toxicology and Nephrotoxicity.”
• Wednesday, 26 March, at 1:00 pm in Exhibit Hall: “Somatic and Germ Cell Mutant Analysis in the Big Blue Transgenic Mouse Mutation Assay with N-Ethyl-N-nitrosourea (ENU)”. Poster number 362
• Wednesday, 26 March, at 1:00 pm in Exhibit Hall: “Integration of Pig-a and Micronucleus Endpoints into the Big Blue Transgenic Mouse Mutation Assay: Results for Benzo(a)pyrene (BaP) and N-Ethyl-N-nitrosourea (ENU)”. Poster number 363
For more information on the Big Blue Mouse and Rat TRM assay service, click here.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance